📊 ERAS Key Takeaways
Is ERAS a Good Investment? Thesis Analysis
Erasca is a pre-revenue biopharmaceutical company with severe cash burn and negative fundamentals across all profitability metrics. With only $73.8M in cash and $95.5M in annual operating cash outflows, the company has approximately 9 months of runway at current burn rates, presenting significant survival risk without additional capital or revenue generation.
Why Buy ERAS? Key Strengths
- Strong balance sheet with $325.2M stockholders equity and minimal leverage (0.00x debt-to-equity)
- Excellent liquidity position with 10.04x current ratio providing near-term operational flexibility
- Low absolute debt burden mitigates downside financial risk
ERAS Investment Risks to Consider
- Pre-revenue stage with no commercial products generating income, entirely dependent on R&D spending
- Severe cash burn of $95.5M annually with only $73.8M cash available, indicating critical dilution or funding risk within 12 months
- Negative ROE of -38.3% and ROA of -31.4% reflect fundamental value destruction, with $124.5M net loss in latest period
- Operating cash flow negative at -$95.6M free cash flow demonstrates unsustainable business model in current state
Key Metrics to Watch
- Cash position and runway; any major financing or capital raise
- Clinical trial progress and regulatory milestones for pipeline assets
- Operating burn rate trends and quarterly cash consumption
ERAS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.04x current ratio provides a solid financial cushion.
ERAS Profitability Ratios
ERAS vs Healthcare Sector
How Erasca, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ERAS Overvalued or Undervalued?
Based on fundamental analysis, Erasca, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ERAS Balance Sheet & Liquidity
ERAS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Erasca, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.69 indicates the company is currently unprofitable.
ERAS Growth Metrics (YoY)
ERAS Capital Allocation
ERAS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Erasca, Inc. (CIK: 0001761918)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ERAS
What is the AI rating for ERAS?
Erasca, Inc. (ERAS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ERAS's key strengths?
Claude: Strong balance sheet with $325.2M stockholders equity and minimal leverage (0.00x debt-to-equity). Excellent liquidity position with 10.04x current ratio providing near-term operational flexibility.
What are the risks of investing in ERAS?
Claude: Pre-revenue stage with no commercial products generating income, entirely dependent on R&D spending. Severe cash burn of $95.5M annually with only $73.8M cash available, indicating critical dilution or funding risk within 12 months.
What is ERAS's revenue and growth?
Erasca, Inc. reported revenue of N/A.
Does ERAS pay dividends?
Erasca, Inc. does not currently pay dividends.
Where can I find ERAS SEC filings?
Official SEC filings for Erasca, Inc. (CIK: 0001761918) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ERAS's EPS?
Erasca, Inc. has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ERAS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Erasca, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ERAS stock overvalued or undervalued?
Valuation metrics for ERAS: ROE of -38.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ERAS stock in 2026?
Our dual AI analysis gives Erasca, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ERAS's free cash flow?
Erasca, Inc.'s operating cash flow is $-95.5M, with capital expenditures of $128.0K.
How does ERAS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -38.3% (avg: 15%), current ratio 10.04 (avg: 2).